Background-Chromogranin B (CgB) is a member of the granin protein family. Because CgB is often colocalized with chromogranin A (CgA), a recently discovered cardiac biomarker, we hypothesized that CgB is regulated during heart failure (HF) development. Methods and Results-CgB regulation was investigated in patients with chronic HF and in a post-myocardial infarction HF mouse model. Animals were phenotypically characterized by echocardiography and euthanized 1 week after myocardial infarction. CgB mRNA levels were 5.2-fold increased in the noninfarcted part of the left ventricle of HF animals compared with sham-operated animals (PϽ0.001). CgB mRNA level in HF animals correlated closely with animal lung weight (rϭ0.74, Pϭ0.04) but not with CgA mRNA levels (rϭ0.20, Pϭ0.61). CgB protein levels were markedly increased in both the noninfarcted (110%) and the infarcted part of the left ventricle (70%) but unaltered in other tissues investigated. Myocardial CgB immunoreactivity was confined to cardiomyocytes. Norepinephrine, angiotensin II, and transforming growth factor-␤ increased CgB gene expression in cardiomyocytes. Circulating CgB levels were increased in HF animals (median levels in HF animals versus sham, 1.23 [interquartile range, 1.03 to 1.93] versus 0.98 [0.90 to 1.04] nmol/L; Pϭ0.003) and in HF patients (HF patients versus control, 1.66 [1.48 to 1.85] versus 1.47 [1.39 to 1.58] nmol/L; Pϭ0.007), with levels increasing in proportion to New York Heart Association functional class (Pϭ0.03 for trend). Circulating CgB levels were only modestly correlated with CgA (rϭ0.31, Pϭ0.009) and B-type natriuretic peptide levels (rϭ0.27, Pϭ0.014). Conclusions-CgB production is increased and regulated in proportion to disease severity in the left ventricle and circulation during HF development. (Circ Heart Fail. 2010;3:503-511.)
A dvances in treatment of acute coronary syndromes have reduced short-term mortality following acute myocardial infarction (MI), but at the cost of a higher incidence of post-MI heart failure (HF). 1 Improved pathophysiological understanding of HF and better tools for risk prediction and diagnostic purposes are therefore needed. 2 The cardiac biomarkers used routinely in clinical practice today are proteins specific to the diseased myocardium, either released during cell necrosis (cardiac specific troponins) 3 or secreted secondary to cardiomyocyte strain (B-type natriuretic peptide, BNP). 4 However, there is still a need for markers reflecting other pathophysiological processes in heart disease. 5 Thus, identifying new proteins regulated in the failing myocardium may potentially improve both the understanding of HF development and lead to the discovery of novel cardiac biomarkers.
Clinical Perspective on p 511
Chromogranin B (CgB) is a 50-kDa protein belonging to a group of acidic proteins called the granin protein family. 6 The most extensively studied and well-known member of the granin family is chromogranin A (CgA), a protein currently used clinically as a biomarker in patients with neuroendocrine tumors. 7 Recently, CgA has been shown to increase with the severity of HF 8 and to be an independent predictor of mortality in patients with acute coronary syndrome. 9 -11 Moreover, increased CgA production has been demonstrated in cardiomyocytes of the failing myocardium. 12 However, a confounding factor possibly reducing CgA's merit as a cardiac biomarker is the increase in CgA levels seen with the use of proton pump inhibitors (PPIs). 13 In contrast, CgB levels appear to be unaffected by PPI use and may provide additional diagnostic information to CgA in patients with neuroendocrine tumors. 14 Additionally, colocalization of CgA and CgB in atrial tissue has been documented, 15 linking CgB to the myocardium and possibly also cardiovascular pathophysiology. Accordingly, we hypothesized that CgB levels in the myocardium and the circulation are increased and closely regulated during HF development.
Methods

Mouse Model of HF
A permanent ligation of the left main coronary artery were performed in mice in the HF group, whereas sham-operated (sham) animals underwent the same procedure except ligation of the coronary artery. 16 Echocardiographic examination was performed 1 week after the primary operation. The criteria for including animals in the HF group have previously been validated. 17
Patients With HF and Healthy Control Subjects
Eighty patients with echocardiographically documented impaired systolic function (left ventricular ejection fraction Յ50%) were included in the clinical part of this study: 70 patients from the Akershus University Hospital outpatient HF clinic and 10 patients hospitalized at Akershus University Hospital for worsening HF with dyspnea as the most prominent symptom. All patients were classified according to the New York Heart Association (NYHA) functional class system by a single investigator (H.R.). Patients with noncurable malignancy and life expectancy Ͻ1 year, acute MI, cardiac surgery, or percutaneous coronary intervention during the last 3 months were not eligible for participation in the study. Accordingly, none of the hospitalized patients were diagnosed with an acute MI.
Twenty control subjects with similar age and sex distribution as the patients were also recruited. These individuals had no history of cardiovascular disease or other concurrent disease, no current symptoms of cardiovascular disease as evaluated by 1 investigator (H.R.), and they did not use medication regularly.
The study protocol was approved by the Regional Ethics Committee before the initiation of the study. All participants gave their written informed consent prior to study commencement.
Quantitative Real-Time PCR
Gene expression was measured with premade TaqMan Gene Expression assays from Applied Biosystems (Foster City, Calif): mouse model: CgB (Mm00483287_m1), CgA (Mm00514341_m1), BNP (Mm00435304_g1), ribosomal protein L4 (RPL4) (Mm00834993_g1); and rat cardiomyocytes: CgB (Rn01514853_m1), CgA (Rn00572200_m1), BNP (Rn00580641_m1), RPL4 (Rn00821091_g1).
Immunoblotting and Immunhistochemistry
A purified polyclonal goat antihuman CgB was used for immunoblotting (1:100 dilution) and immunhistochemistry (Sc-1489, Santa Cruz Biotechnology, Santa Cruz, Calif). This antibody showed strong and specific binding to the C-terminal region of CgB (see Online-only Data Supplement, Figure S1 ). A secondary antibody (diluted 1:2500) against goat (6160 -05) was used for immunoblotting (Southern Biotech, Birmingham, Ala). CgA immunoreactivity in mouse myocardial sections was detected by a purified polyclonal rabbit antihuman CgA antibody (Sc-13090, Santa Cruz).
Radioimmunoassay
Plasma CgB levels were measured by an in-house made regionspecific radioimmunoassay (RIA) detecting CgB439 -451, 18 plasma CgA levels by a commercial RIA identifying CgA116 -439 (Euro-Diagnostica, Malmö, Sweden), and left ventricular (LV) tissue CgA levels with an in-house made region-specific RIA detecting CgA361-372. 19 
Cell Culture Experiments
Statistical Analysis
Continuous data are presented as mean (ϮSEM) or median and interquartile range (IQR) and categorical values as counts (percentage). Continuous variables were compared by the Student t test except circulating biomarker values that were compared by the Mann-Whitney U test due to a right-skewed distribution. Categorical variables were compared by the 2 test or Fisher exact test as appropriate. Correlations and trends were calculated using Spearman rank correlation. Probability values Ͻ0.05 were considered significant for all analyses. Statistical analyses were performed with SPSS for Windows version 14.0 (SPSS, Chicago, Ill).
Details regarding methods can be found in the online-only Data Supplement. The authors (H.R., T.O., and G.C.) had full access to the data and take responsibility for its integrity. All authors have read and agreed to the manuscript as written.
Results
Characteristics of Animals
We used a post-MI mouse HF model to study CgB production in various tissues during HF development. As shown in Table 1 , the animals included in the post-MI group had clear evidence of HF and compensatory myocardial hypertrophy.
LV CgB Gene Expression Is Increased and Closely Regulated in HF
To investigate regulation of CgB gene expression in the LV during HF development, CgB mRNA levels in noninfarcted tissue of HF animals were compared with levels in sham animals. CgB mRNA levels were 5.2 times upregulated in HF animals ( Figure 1A ). Moreover, because CgB mRNA levels in HF animals correlated with animal lung weights (rϭ0.74, Pϭ0.04, Figure 1B ), LV CgB gene expression appears to be closely regulated in proportion to disease severity during HF development. CgA mRNA levels were also increased in HF animals (4.8-fold increase, Pϭ0.025), but there was no significant correlation between LV CgA and CgB mRNA levels in HF (rϭ0.20, Pϭ0.61) or sham animals (rϭ0.57, Pϭ0.14). We found no change in gene expression between nonoperated control animals and sham animals, and RPL4 gene expression was similar in the different groups.
CgB Protein Levels Are Increased in Both Noninfarcted and Infarcted LV Tissue in HF
To further study CgB production in HF, we measured CgB protein levels in the LV of HF and sham animals. Supporting our gene expression data, CgB protein levels were clearly increased in both noninfarcted and infarcted LV tissue of HF animals (110% and 70% increase, respectively, Figure 2 ). CgA protein levels were also increased in noninfarcted LV tissue (40% increase, Pϭ0.002), whereas there was no change in infarcted LV tissue.
CgB levels were not different in sham animals compared with nonoperated control animals.
CgB Levels in Non-LV Tissue Were Unaffected by HF Development
To investigate if increased CgB production is restricted to the LV during HF development, we also assessed CgB produc-tion in other tissues. No elevation of CgB levels were found in the right ventricle, pulmonary tissue, liver, spleen, kidney, stomach, colon, or skeletal muscle of HF animals (Figure 3 ), supporting the notion that increased CgB production may be specific to the LV in HF.
CgB Production in the Myocardium Is Confined to Cardiomyocytes
Immunohistochemistry was performed to identify the cells in the myocardium that synthesize CgB. As shown in Figure 4 , fairly strong immunostaining for CgB was found in cardiomyocytes in noninfarcted myocardial tissue, whereas weaker staining was observed in the infarcted region of the LV confined to scattered surviving cardiomyocytes. No other cell type was found to produce CgB in the myocardium. Myocardial CgA production was also confined to the cardiomyocytes (Figure 4) , reflecting that the chromogranins are a family of proteins produced by the cardiomyocytes during HF development.
No or very weak staining was seen in the negative control sections stained with omission of the primary antibody or with the use of nonimmune antiserum, respectively.
CgB Gene Expression in Cardiomyocytes Is Increased by NE, AngII, and TGF-␤
To elaborate on the mechanism for increased cardiomyocyte CgB production in HF, we investigated the influence of signaling molecules known to be regulated in HF on cardiomyocyte CgB gene expression. NE, AngII, and TGF-␤ all potently upregulated cardiomyocyte CgB gene expression ( Figure 5 ). In contrast, ET-1 and TNF-␣ had no effect on cardiomyocyte CgB gene expression. FSK, known to upregulate CgB gene expression in other cell types, 21 also increased CgB gene expression in cardiomyocytes.
In a second set of experiments, these hormones and cytokines had no effect on cardiomyocyte CgA production, whereas BNP mRNA levels were increased by NE (200%), ET-1 (90%), and FSK (60%) (PϽ0.001 for all). RPL4 gene expression was not affected by any of the stimuli.
Circulating Levels of CgB Are Increased and Regulated in HF
Because circulating levels of CgA have been found to predict mortality in patients with both HF 8 and acute coronary syndrome, 9 -11 we next investigated if also circulating CgB levels are regulated during HF development. In the experimental model, circulating CgB levels were clearly increased in HF animals compared to sham-operated animals (median, 1.23 [IQR: 1.03 to 1.93] versus 0.98 [0.90 to 1.04] nmol/L; Pϭ0.003; Figure 6A ), confirming that circulating levels of CgB are increased in HF. There was no difference in circulating CgB levels in nonoperated control animals and sham-operated animals.
To investigate whether CgB may have potential as a cardiac biomarker, we sought to validate our experimental data in the clinical condition. Circulating CgB levels were measured in a heterogeneous group of HF patients and compared to levels in age-and sex-matched healthy control subjects. Characteristics of patients and control subjects are presented in Table 2 . In general, patients had chronic HF of mainly moderate severity with 18 months median duration of symptoms, a mean LV ejection fraction of 33%, a median BNP level of 223 pg/mL, and 67% of patients were classified in NYHA functional class II. Patients were treated according to updated guidelines. Median duration of HF symptoms was similar in patients recruited from the ambulatory HF clinic and hospitalized patients as the latter group consisted mainly of patients with acute-on-chronic HF (see online-only Data Supplement for further descriptive statistics of HF patients). In this cohort of patients with HF of mainly moderate severity, circulating CgB levels were significantly increased compared with the healthy control subjects (median, 1.66 [IQR: 1.48 to 1.85] versus 1.47 [1.39 to 1.58] nmol/L; Pϭ0.007; Figure 6B ). Furthermore, circulating CgB levels increased in proportion to severity of HF as evaluated by NYHA functional class (Pϭ0.03 for trend). We found no difference in CgB levels in patients with HF caused by ischemic etiology compared with patients diagnosed with dilated cardiomyopathy ( . CgB and CgA production in the myocardium. Representative photomicrographs of myocardial tissue sections of a HF mouse demonstrating CgB immunoreactivities (brown staining) detected in nonischemic cardiomyocytes bordering the infarcted zone (border zone, lower left). Similar immunostaining was also found in the remote noninfarcted myocardium (upper left). In the infarcted region (upper middle), only weak CgB immunostaining was detected. Bottom picture in the middle demonstrates very weak staining after use of nonimmune rabbit serum as control (ctr). CgA immunoreactivities (brown staining) were also confined to cardiomyocytes as illustrated by photomicrographs of the border zone and the infarcted myocardium (far right). Magnification ϫ200.
Figure 5.
Influence of signaling molecules known to be regulated in HF on cardiomyocyte CgB gene expression. CgB mRNA levels were measured by quantitative real-time PCR after stimulating neonatal rat cardiomyocytes for 24 hours with either PBS (nϭ11), FSK (nϭ5), NE (nϭ5), AngII (nϭ3), ET-1 (nϭ5), TGF-␤ (nϭ6), or TNF-␣ (nϭ9). CgB mRNA levels are presented as meansϮSEM versus PBS-stimulated cells (ctr). *PϽ0.01, **PϽ0.001.
Discussion
The present study demonstrates for the first time that production of CgB, a member of the granin protein family, is regulated in accordance with disease severity in both experimental and clinical HF. Mice with post-MI HF had markedly increased LV CgB gene expression, proportional to the degree of pulmonary congestion, and CgB protein levels were also elevated in the LV during HF development. Notably, CgB production was not increased in other tissues investigated. The production of CgB in the myocardium was confined to the cardiomyocytes. Moreover, in vitro experiments revealed that NE, AngII, and TGF-␤ all increased cardiomyocyte CgB gene expression. Finally, we found increased circulating levels of CgB in both experimental and clinical HF.
Our criteria for including animals in the HF group have been validated previously, 17 and animals in this group had clear evidence of HF as reflected by severe pulmonary congestion, significantly increased LV and right ventricular mass, and upregulated LV BNP gene expression. Interestingly, HF animals also had clearly increased LV CgB gene expression and protein levels, suggesting de novo LV CgB production in HF. Moreover, as LV CgB gene expression in HF animals was closely correlated with animal lung weights, CgB production in the myocardium appears to be regulated during HF development. Our findings are in line with another report published during progression of our work demonstrating increased LV CgB production in a mouse model of AngII-induced LV hypertrophy. 22 By immunohistochemistry, we demonstrated that CgB production is confined to the cardiomyocytes in the myocardium. We postulate that the myocardium may be an important source of increase in circulating CgB levels found in HF because (1) CgB production was increased in a closely regulated manner in the LV during HF development, (2) no regulation of CgB production was found in any other organ investigated, and (3) CgB and the chromogranins are considered marker-proteins for exocytosis in numerous cell types. 23 The mechanism for increased CgB production in cardiomyocytes was investigated in vitro. We used FSK as a positive control as the CgB promoter contains a cAMP response element. 24 NE has been found to activate cAMP response element transcription sites through both ␣ 1 -and ␤-adrenergic receptor signaling, 25, 26 and NE-induced increase in CgB gene expression may reflect CgB stimulustranscription-secretion coupling in the myocardium during HF, a mechanism known to be important for CgB production and secretion in nonmyocardial tissue. 21 Because circulating NE levels in HF are increased in proportion to patient NYHA functional class, 27 the effect of NE on cardiomyocyte CgB production, and possibly also secretion, may explain the close association found between CgB levels in the myocardium and plasma and indices of severity of HF. However, additional studies are needed to precisely characterize the effect of NE on cardiomyocyte CgB exocytosis and the relative importance of NE versus the effect by AngII and TGF-␤ on CgB production and secretion.
To our knowledge, no previous study has examined CgB production or circulating CgB levels during HF development. Increased CgB production has been found in neuroendocrine tumors, 28 and circulating CgB levels have been proposed as a potential biomarker in patients with neuroendocrine tumors. 14, 29 The demonstration of increased circulating CgB levels during HF development suggests that CgB may potentially represent a novel cardiac biomarker. This notion is supported by regulation of circulating CgB levels in proportion to NYHA functional class. However, the relative increase in circulating CgB levels in HF individuals was larger in the animal model than in the clinical study, indicating that CgB production may be more potently induced in the early phase of HF development compared with the stable, chronic phase. A trend for higher CgB levels in hospitalized than in ambulatory patients ( Supplemental Table S1 and Figure S2 ) is also compatible with the theory that acute decompensation may lead to higher CgB levels than observed in the chronic state. Furthermore, contemporary HF therapy may have contributed to lower CgB levels in stable ambulatory patients.
CgB has been reported to be robust and stable in vitro, with only 3.7% degradation found in plasma samples stored at room temperature for 24 hours. 29 In addition, circulating CgB levels were unaffected by PPI use, a medication currently recommended as a prophylactic measure in many patients with heart disease, 30 and with well-known stimulatory effects on CgA production. 13 Moreover, few other conditions are known to be associated with increased circulating CgB levels. In fact, except for the rare neuroendocrine tumors, 14, 29, 31, 32 confounding by other diseases does not seem to represent a major problem for use of CgB as a marker of cardiac status.
Even in prostate cancer patients with metastatic disease and tumors with widespread neuroendocrine differentiation, only 14% of patients had increased circulating CgB levels, whereas 59% of patients had increased CgA levels. 33 Taken together, this information suggests that the collection and handling of blood samples is relatively simple for CgB.
Reports on circulating CgB levels in association with cardiovascular disease are scarce, but 1 study investigated the association between presurgery CgB levels and postsurgery atrial fibrillation in patients undergoing coronary by-pass grafting. 34 The authors found no difference in CgB levels between patients developing arrhythmias and patients in stable sinus rhythm after surgery, opposing the hypothesis that CgB levels could reflect autonomous imbalance. In contrast, a polymorphism in the CgB gene was reported to be the strongest predictor of enhanced vasoconstriction in a study assessing association between single nucleotide polymorphisms in the adrenergic pathway and venous vasoconstriction. 35 The net effect of increased circulating CgB levels in HF patients with regard to autonomic nervous system tone is not clear and will require additional investigations. Increased CgB levels may also have direct effects on the cardiomyocytes and the myocardium. CgB, in contrast to CgA, translocates to the nucleus and has been found to regulate gene transcription, including increasing myocyte enhancer factor 2 (MEF2) production, 36 a well-known prohypertrophic factor in the myocardium. 37 CgB is also considered an important modulator of the inositol 1,4,5-triphosphate receptor (IP3R), 38 and recently, CgB was shown to regulate AngII-induced myocardial hypertrophy in vitro by modifying Ca 2ϩ release from the sarcoplasmic reticulum through the IP3R. 22 The augmentation of IP3R-mediated Ca 2ϩ release by CgB may also be of importance for the generation of ventricular arrhythmias in HF because the IP3R recently was shown to regulate ryanodine receptor stability during myocardial remodeling. 39 Because both CgB and the IP3R 40 are upregulated in the failing myocardium, this CgB-IP3Rcomplex may be responsible for altered Ca 2ϩ homeostasis resulting in increased susceptibility to arrhythmias. Additionally, as CgB production in cardiomyocytes is closely regulated by NE, CgB levels in the myocardium, and potentially also in the circulation, may integrate information on cardiomyocyte NE stimulation and IP3R activity, both risk factors for development of ventricular arrhythmias. Still, similar to the situation of other recently proposed markers, more work is needed to establish CgB as a clinically useful HF biomarker (Table 3 ). Of note, CgA also binds to the IP3R but seems to be inferior to CgB for regulation of IP3R activity. 38 In contrast, fragments of CgA have been found to affect several important processes in HF such as myocardial contractility, endothelial function, and arterial tone, 41 whereas such effects have not been recognized for CgB fragments. A comparison of CgA and CgB is provided in Table 4 ; however, the relative merit of circulating CgA and CgB as cardiac biomarkers must be further characterized.
The main limitation of this study is lack of data relating CgB to outcome in patients with HF. The HF patient cohort is of modest size and consists of patients with both ischemic and nonischemic HF, and acute and chronic HF. Our data for CgB as a cardiac biomarker clearly needs to be validated in larger HF cohorts, both regarding diagnostic and prognostic utility. Consequently, the current study should be considered a phase one/proof of concept investigation of CgB as a cardiac biomarker. 42 In conclusion, we have found increased CgB production in LV cardiomyocytes from post-MI HF animals proportional to HF severity. Because cardiomyocyte CgB gene expression was increased by NE, AngII, and TGF-␤, myocardial CgB levels may reflect alterations in important hormonal and paracrine mediators in HF. Furthermore, circulating CgB levels were increased in both HF animals and in patients with HF of mainly moderate severity, again proportionate to HF severity. Moreover, as CgB production was not altered in other organs investigated, the increased circulating levels may at least partly reflect enhanced CgB production in the LV. Finally, because circulating CgB levels were not affected by PPI use and increased in HF patients, CgB may represent a potential new HF biomarker, but this must be validated in larger clinical studies. 
